Dosing & Administration
Oral and IV Monotherapy Dosing
With BAXDELA® (delafloxacin)
Oral or IV q12h dosing
No Oral Dosage Adjustment Required Due To:
BAXDELA is not recommended in patients with End Stage Renal Disease (ESRD) (eGFR >15 mL/min/1.73 m2), including patients on hemodialysis, due to insufficient information for dosing recommendations.
Fixed-Dosage Adjustment in IV Formulation for Patients with Severe Renal Impairment (eGFR 15-29 mL/min/1.73 m2)
- 200 mg IV q12h
OR
- 200 mg IV q12h, then switch to a 450-mg BAXDELA tablet orally q12h at the discretion of the physician
Melinta Therapeutics, LLC - Unparalleled in passion & purpose
Medical Information
For medical inquiries or to report an adverse event, other safety-related information, or product complaints for a company product, please contact Medical Information.
Phone: 1-844-MED-MLNT (1-844-633-6568)
medinfo@melinta.com
www.melintamedicalinformation.com
©2021 All rights reserved. PP-BAX-US-0399 Terms of Use
BAXDELA® is indicated in adults for the treatment of acute bacterial skin and skin structure infections (ABSSSI) and community-acquired bacterial pneumonia (CABP) caused by designated susceptible bacteria.